FINWIRES · TerminalLIVE
FINWIRES

Arcus Biosciences Discontinues Phase 3 Lung Cancer Trial for Futility

-- Arcus Biosciences (RCUS) said Monday it discontinued its phase 3 STAR-121 study in metastatic non-small cell lung cancer after an Independent Data Monitoring Committee recommended stopping the trial for futility.

The study, conducted in collaboration with Gilead Sciences (GILD), evaluated domvanalimab plus zimberelimab and chemotherapy versus pembrolizumab plus chemotherapy as a first-line treatment, the company said.

The decision followed a pre-planned futility analysis indicating the treatment was unlikely to meet its primary endpoint.

Shares of Arcus Biosciences were down 5% in Monday trading.

Price: $23.05, Change: $-1.20, Percent Change: -4.95%

Related Articles

Research

Research Alert: Crown Castle Inc. Q1: Revenue And Ffo Beat, Fiber Sale Expected To Close In Q2

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CCI reported Q1 revenue of $1.01B, down 4.8% Y/Y from $1.06B but beating consensus estimates by $16M. Site rental revenues declined 5% Y/Y to $961M, primarily driven by the anticipated $49M impact from DISH contract terminations and $5M from Sprint cancellations. Management left site rental revenue guidance unchanged at -5% at the midpoint to $3.85B for the full year. Excluding the impact of DISH and Sprint churn this year, management expects 3.5% organic growth for 2024. However, organic growth moderated to 3.1% in Q1 from 3.9% in the prior-year quarter, indicating some softening in underlying leasing momentum across the tower portfolio. The DISH contract terminations continue to represent a significant operational and financial headwind for CCI's near-term performance trajectory, though the company appears to be successfully managing through this challenging transition period while maintaining its full-year revenue outlook and guidance.

$CCI
Research

Research Alert: Csx Beats Q1 Consensus Estimates, Reflecting Improved Efficiency

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CSX reported Q1 EPS of $0.43 vs. $0.34 in the prior year, beating consensus by $0.04, while revenue of $3.48B met estimates and rose 2% Y/Y. Operating margin expanded significantly to 36.0% from 30.4%, reflecting a 560-bp improvement that underscores operational efficiency progress. We view this as a solid turnaround after CSX missed expectations in the prior quarter due to weak industrial demand. Revenue growth was driven by higher merchandise pricing, strong 6% intermodal volume growth, and increased fuel surcharge revenue. CSX achieved meaningful operational improvements with train velocity up 7% to 18.9 mph, dwell time improving 7% to 10.7 hours, and carload trip plan performance rising 7% to 74%. The company delivered solid expense management as total costs declined $153M despite inflationary pressures, with labor expenses down $9M even after absorbing $41M in inflation increases, demonstrating workforce optimization benefits that reduced average rail headcount by 1,177 employees.

$CSX
US Markets

Nasdaq, S&P 500 Notch Peaks as Earnings Fuel Optimism

The Nasdaq Composite and the S&P 500 hit record highs on Wednesday as upbeat corporate results overshadowed a rise in oil prices following Iran's seizure of two container ships in the Strait of Hormuz.The Nasdaq rose 1.6% to 24,657.6, while the S&P 500 climbed 1.1% to 7,137.9, both finishing at all-time highs after a two-day losing streak. The Dow Jones Industrial Average added 0.7% to 49,490.Most sectors were in the green, led by technology's 2.3% advance, while real estate saw the steepest decline.Boeing's (BA) first-quarter loss unexpectedly narrowed as commercial aircraft deliveries rose, while the plane maker reported a smaller cash burn year over year. The stock jumped 5.5%, the best performer on the Dow.Boston Scientific (BSX) shares surged 9%, the third-biggest gain on the S&P 500. The medical device supplier's first-quarter results exceeded Wall Street's estimates, but it lowered its full-year guidance.Philip Morris International (PM) reported first-quarter results above market estimates, while lowering its full-year earnings outlook. The cigarette and vape maker's shares jumped 7%.A number of tech stocks climbed, with Micron (MU) up 8.5%, among the biggest gains on the S&P 500. Apple (AAPL) rose 2.6%, the second-best performer on the Dow. Microsoft (MSFT) and Salesforce (CRM) also rose.West Texas Intermediate crude rose 3.3% to $92.58 per barrel in Wednesday late-afternoon trade, while Brent jumped 3% to $101.44.Iran said it seized two container ships attempting to cross the Strait of Hormuz, a key oil chokepoint. US President Donald Trump extended a ceasefire with Tehran late Tuesday, though he said the naval blockade of Iranian ports would continue.The status of a second round of peace talks between the US and Iran remained unclear.Trump does not consider Iran's claim that it seized two ships as a violation of the ceasefire, CNN reported, citing White House Press Secretary Karoline Leavitt.Tehran welcomes dialogue, but "breach of commitments, blockade and threats are main obstacles to genuine negotiations," Iranian President Masoud Pezeshkian said in a post on X on Wednesday."Oil prices continue to whipsaw as traders respond to a confusing and often contradictory flow of headlines, underscoring the deep mistrust between Tehran and Washington," Saxo Bank Head of Commodity Strategy Ole Hansen said in a report on Wednesday.US Treasury yields were mixed, with the 10-year rate little changed at 4.31% and the two-year rate up 2.7 basis points at 3.81%.Gold was up 0.9% at $4,759.60 per troy ounce, while silver gained 1.7% to $77.75 per ounce.

$^DJI$^IXIC$^SPX$AAPL$BA$BSX$CRM$MSFT$MU$PM